Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914405 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
A Phase 1 study of Neuroblastoma, sponsored by University Hospital Southampton NHS Foundation Trust.
- Active
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 3
- Study locations
NCT02914405 is a Phase 1 study of Neuroblastoma that is active but no longer recruiting, run by University Hospital Southampton NHS Foundation Trust. The registered enrollment target is 44 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02914405, a Phase 1 study of Neuroblastoma, is active but no longer recruiting, sponsored by University Hospital Southampton NHS Foundation Trust.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 3
- Study locations
Study Summary
Neuroblastoma, the most common extra-cranial solid tumour in children, remains one of the major challenges in paediatric oncology. A promising way to further improve outcome in this disease appears to be the development of adjuvant therapeutic strategies. In this research the anti-GD2 antibody, which is a standard treatment, is to be combined with 131-l Metaiodobenzylguanidine (mlBG) and anti-Programmed Cell Death Protein 1 (anti-PD1) antibody Nivolumab - the investigated drugs - with the aim of generating sustained anti-neuroblastoma immunity. In particular it will be determined the safety and tolerability of the novel combination as well as documented any evidence of efficacy in paediatric patients with relapsed and refractory high risk neuroblastoma. This study is sponsored by the University Hospital Southampton and will take place in 4 hospitals in the United Kingdom, Germany and USA. The estimated duration of the study is 2 years, starting in December 2016. This is an "adaptive study". Such design uses accumulating of data from the ongoing trial to modify aspects of the study (e.g. duration, number of treatments) without undermining its validity or integrity. There will be 3 cohorts of patients. As safety of Nivolumab is well established, Cohort 1 will assess its safety and tolerability in combination with 131-l mlBG. Cohort 2 will then add anti-GD2 to the drug combination, assessing safety and tolerability. Cohort 3 will escalate all 3 agents to the full 100% dose level to assure safety for expanded analyses of clinical and laboratory data at that dose level. Patients will initially be recruited into Cohort 1. Patients must have completed at least 12 weeks of trial treatment without reaching a Dose Limiting Toxicity before a patient can be recruited to the next cohort. A minimum of 3 evaluable patients will be treated in cohorts 1-3. Assuming the full dose combination therapy (cohort) is tolerable, 15 evaluable patients will be treated.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ch14.18/CHO
Study Locations (3)
Wisconsin
- University of Wisconsin Carbone Cancer Center; UW Hospital and Clinics; American Family Children's Hospital - Madison
Hampshire
- University Hospital Southampton NHS Foundation Trust - Southampton
London
- University College London Hospital - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-05-24 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914405
The ClinicalTrials.gov registry entry for NCT02914405 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (82% lower). The listed sponsor is University Hospital Southampton NHS Foundation Trust, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT02914405 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Wisconsin, Hampshire, London.
Frequently Asked Questions
What is clinical trial NCT02914405 about?
NCT02914405 is a clinical study titled "Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma". Neuroblastoma, the most common extra-cranial solid tumour in children, remains one of the major challenges in paediatric oncology. A promising way to further improve outcome in this disease appears to be the development of adjuvant therapeutic strategies. In this research the anti-GD2 antibody, whic...
What is the current status of trial NCT02914405?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2018-05-24. Estimated completion is 2025-11-30.
What conditions does trial NCT02914405 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT02914405?
The interventions under investigation include: Nivolumab (DRUG), Ch14.18/CHO (DRUG).
Who is sponsoring clinical trial NCT02914405?
This trial is sponsored by University Hospital Southampton NHS Foundation Trust, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914405 being conducted?
This trial has 3 study locations across Wisconsin, Hampshire, London. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.